---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-056454"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2026-08-13T10:14:04+00:00"
generated_at: "2026-08-13T10:15:06.578439+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical Q2 net sales up 11% to $17.8M; net loss narrows to $1.2M

## Summary
- Net sales $17.8M, +11% YoY; gross profit $3.2M, +30%; gross margin 18% vs 16%.
- Net loss $1.2M vs $1.5M loss; adjusted EBITDA -$0.2M; cash $24.8M at June 30.
- Reiterates 2026 guidance: net sales $70-75M, gross margin 18-22%, adj EBITDA $1-2M.
- 1-for-10 reverse stock split effective July 1, 2026; regained Nasdaq compliance.
- New/expanded agreements with Heritage Dialysis and aQua Dialysis during Q2.

## SEC filing metadata
- accession: 0001628280-26-056454
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2026-08-13T10:14:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000162828026056454/0001628280-26-056454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000162828026056454/rmti-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-056454
- JSON: https://secwatch.observer/filing/0001628280-26-056454.json
- Plain text: https://secwatch.observer/filing/0001628280-26-056454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.